Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Dyax Corp.
Sponsor:
Information provided by (Responsible Party):
Dyax Corp.
ClinicalTrials.gov Identifier:
NCT02093923
First received: March 17, 2014
Last updated: September 11, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to evaluate the safety, tolerability, and PK profile of multiple subcutaneous administrations of DX-2930 across a range of doses in HAE subjects.


Condition Intervention Phase
Hereditary Angioedema
Drug: DX-2930
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects

Resource links provided by NLM:


Further study details as provided by Dyax Corp.:

Primary Outcome Measures:
  • proportion of patients with non-serious and serious adverse events [ Time Frame: through 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • DX-2930 plasma level [ Time Frame: through 4 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 18
Study Start Date: April 2014
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DX-2930, Cohort 1
DX-2930 administered twice, two weeks apart
Drug: DX-2930
DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody
Drug: Placebo
Placebo
Experimental: DX-2930, Cohort 2
DX-2930 administered twice, two weeks apart
Drug: DX-2930
DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody
Drug: Placebo
Placebo
Experimental: DX-2930, Cohort 3
DX-2930 administered twice, two weeks apart
Drug: DX-2930
DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody
Drug: Placebo
Placebo
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • At least 18 years of age at the time of screening.
  • Documented diagnosis of HAE (Type I or II)
  • Experiencing ≥2 HAE attacks per year, with at least 1 attack in the past 6 months reported by the subject.
  • Willing and able to read, understand, and sign an informed consent form.
  • Females of childbearing potential must agree to be abstinent or else use acceptable forms of contraception throughout study
  • Males with female partners of childbearing potential must agree to be abstinent or use a medically acceptable form of contraception throughout study.

Exclusion Criteria:

  • Exposure to an investigational drug or device within 90 days prior to study.
  • History of exposure within the past 5 years to a monoclonal antibody or recombinant protein bearing an Fc domain.
  • Concomitant diagnosis of another form of chronic angioedema
  • Use of long-term prophylaxis for HAE within 90 days prior to study.
  • Use of C1-INH that exceeds a total of 30 days within the past 90 days prior to study; any use of C1-INH within 7 days prior to study.
  • Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption within 90 days prior to study.
  • Exposure to androgens within 90 days prior to study.
  • Presence of an indwelling catheter.
  • Diagnosis of HIV.
  • Active liver disease or liver function test abnormalities
  • History of substance abuse or dependence.
  • Pregnancy or breastfeeding.
  • Any condition that, in the opinion of the Investigator, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02093923

Contacts
Contact: Ryan Iarrobino 617-250-5574 riarrobino@dyax.com

Locations
United States, California
Allergy & Asthma Clinical Research Recruiting
Walnut Creek, California, United States, 94598
Principal Investigator: Joshua S Jacobs, MD         
United States, Florida
University of South Florida Asthma, Allergy or Immunology Clinical Research Unit Recruiting
Tampa, Florida, United States, 33613
Principal Investigator: Richard F Lockey, MD         
United States, Maryland
Institute for Asthma & Allergy, PC Recruiting
Chevy Chase, Maryland, United States, 20815
Principal Investigator: H. Henry Li, MD, PhD         
United States, Massachusetts
Massachusetts General Hospital Allergy Associates Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Aleena Banerji, MD         
United States, Missouri
Washington University School of Medicine Recruiting
St. Louis, Missouri, United States, 63110
Principal Investigator: H. James Wedner, MD         
United States, New York
Winthrop-University Hospital, Clinical Trials Center Recruiting
Mineola, New York, United States, 11501
Principal Investigator: Mark Davis-Lorton, MD         
Icahn School of Medicine at Mount Sinai - The Mount Sinai Medical Center Recruiting
New York, New York, United States, 10029
Principal Investigator: Paula Busse, MD         
United States, Ohio
UC Physicians Company Recruiting
Cincinnati, Ohio, United States, 45267
Principal Investigator: Jonathan A Bernstein, MD         
United States, Oregon
Baker Allergy, Asthma and Dermatology Research Center Recruiting
Lake Oswego, Oregon, United States, 97035
Principal Investigator: James W Baker, MD         
United States, Texas
AARA Research Center Recruiting
Dallas, Texas, United States, 75231
Principal Investigator: William R Lumry, MD         
Jordan
Jordan University Hospital Recruiting
Amman, Jordan, 11942
Principal Investigator: Mustafa Shennak, MD         
Sponsors and Collaborators
Dyax Corp.
  More Information

No publications provided

Responsible Party: Dyax Corp.
ClinicalTrials.gov Identifier: NCT02093923     History of Changes
Other Study ID Numbers: DX-2930-02
Study First Received: March 17, 2014
Last Updated: September 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Dyax Corp.:
HAE

Additional relevant MeSH terms:
Angioedemas, Hereditary
Angioedema
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, Inborn
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on September 16, 2014